Bayer Takes On 2 More Generics Makers Over Yasmin
In a complaint filed Friday with the U.S. District Court for the Southern District of New York, Bayer alleges that Watson and Sandoz infringed one of its patents by filing abbreviated new drug applications for drospirenone and ethinyl estradiol tablets.
Drospirenone and ethinyl estradiol are the active ingredients in Yasmin.
Watson, a Corona, Calif.-based specialty pharmaceutical...
To view the full article, register now.